US02157Q1094 - Common Stock
ALTO NEUROSCIENCE INC
NYSE:ANRO (11/22/2024, 8:23:18 PM)
After market: 4.4496 +0.14 (+3.24%)4.31
+0.22 (+5.38%)
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. The company is headquartered in Los Altos, California and currently employs 67 full-time employees. The company went IPO on 2024-02-02. The firm is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.
ALTO NEUROSCIENCE INC
650 Castro Street, Suite 450
Los Altos CALIFORNIA
P: 17732555012
Employees: 78
Website: https://www.altoneuroscience.com/
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc....
Here you can normally see the latest stock twits on ANRO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: